Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Med BioGene Inc. (MBI) - Financial and Strategic SWOT Analysis Review

VIEWS: 39 PAGES: 44

Med BioGene Inc. (MBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Med BioGene Inc. (MBI) is a life sciences company. It undertakes the development of genomic-based cl

More Info
									       Med BioGene Inc. (MBI) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDME22296FSA                                                                                          Publication Date: JUN 2013

          510 – 580 Hornby Street                            Phone              +1 800 6413593                  Revenue          NA
          Vancouver, BC                                      Fax                +1 888 6462531                  Net Profit       1.53 (million USD)
          V7Y 1C6                                            Website            www.medbiogene.com              Employees        NA
                                                                                MBI   [TSX         Venture
          Canada                                             Exchange                                           Industry         Medical Equipment
                                                                                Exchange]

       Company Overview
       Med BioGene Inc. (MBI) is a life sciences company. It undertakes the development of genomic-based clinical laboratory
       diagnostic tests for cancer. The company manages license and rights to its lead test under development, GeneFx Lung. GeneFx
       Lung is a prognostic genomic-based test for early stage non-small cell lung cancer (NSCLC) that analyzes the molecular profile of
       the tumor in the patient, and delivers information providing assistance in the treatment of patient. MBI has collaborations with the
       Princess Margaret Hospital in Toronto and the University Health Network for the development of its product, GeneFx Lung. MBI is
       headquartered in Vancouver, Canada.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Med BioGene Inc., SWOT Analysis
         Erinn B. Broshko                    Chairman                                 Strengths                              Weaknesses
         Heiner Dreismannm, Ph.D.            Director
                                                                                      GeneFx Lung                            No Commercialized Products
         Dennis L. Grimaud                   Director
         Kevin K. Rooney                     Director
                                                                                      Opportunities                          Threats
         Scott Davis                         Chief Financial Officer
        Source: Annual Report, Company Website, Primary and Secondary                 Strategic Collaborations               Industry Consolidation
        Research, GlobalData
                                                                                      Changing Demographics                  Competitive Landscape
       Share Data
         Med BioGene Inc.
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Share Price (CAD) as on 04-Jun-                                  0.14        GlobalData
        2013
        EPS (CAD)                                                        0.02
        Market Cap (million CAD)                                           10
        Enterprise Value (million CAD)                                     10
        Shares Outstanding (million)                                       78
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      May 30, 2013         Med BioGene Reports Q1 2013 Results
                                                                                      Apr 09, 2013         Med BioGene Reports 2012 Results
                                                                                      Feb 25, 2013         Med Biogene Provides Update On Litigation
                                                                                                           With Signal Genetics And Respira Health
                                                                                      Nov 29, 2012         Med BioGene Reports Q3 2012 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Med BioGene Inc. (MBI) - Financial and Strategic SWOT Analysis                                                                 Reference Code: GDME22296FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Med BioGene Inc. - Key Facts............................................................................................................................................................ 5
       Med BioGene Inc. - Key Employees ................................................................................................................................................... 6
       Med BioGene Inc. - Key Employee Biographies................................................................................................................................. 7
       Med BioGene Inc. - Major Products and Services .............................................................................................................................. 8
       Med BioGene Inc. - Medical Equipment Pipeline Products Data ........................................................................................................ 9
          Med BioGene Inc. Pipeline Products by Equipment Type............................................................................................................... 9
          Med BioGene Inc. Pipeline Products by Development Stage ....................................................................................................... 11
       Med BioGene Inc. - History .............................................................................................................................................................. 13
       Med BioGene Inc. - Company Statement ......................................................................................................................................... 15
       Med BioGene Inc. - Locations And Subsidiaries .............................................................................................................................. 18
          Head Office ................................................................................................................................................................................... 18
          Other Locations & Subsidiaries ..................................................................................................................................................... 18
       Section 2 – Company Analysis ......................................................................................................................................................... 19
       Med BioGene Inc. - Business Description ........................................................................................................................................ 19
       Med BioGene Inc. - SWOT Analysis ................................................................................................................................................ 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          Med BioGene Inc. - Strengths....................................................................................................................................................... 20
             Strength - GeneFx Lung ............................................................................................................................................................ 20
          Med BioGene Inc. - Weaknesses ................................................................................................................................................. 20
             Weakness - No Commercialized Products ................................................................................................................................ 20
          Med BioGene Inc. - Opportunities ................................................................................................................................................. 20
             Opportunity - Strategic Collaborations....................................................................................................................................... 20
             Opportunity - Changing Demographics ..................................................................................................................................... 21
             Opportunity - Need for Better Prognostic Tools......................................................................................................................... 21
          Med BioGene Inc. - Threats .......................................................................................................................................................... 21
             Threat - Industry Consolidation ................................................................................................................................................. 21
             Threat - Competitive Landscape ............................................................................................................................................... 21
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 21
       Med BioGene Inc. - Key Competitors ............................................................................................................................................... 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance...................................................................................................................................................................... 25
       Financial Ratios - Interim Ratios....................................................................................................................................................... 26
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
          Med BioGene Inc., Medical Equipment, Deals By Year, 2007 to YTD 2013 ................................................................................. 28
          Med BioGene Inc., Medical Equipment, Deals By Type, 2007 to YTD 2013................................................................................. 29
          Med BioGene Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ............................................................... 30
          Med BioGene Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ............................................................... 31


Med BioGene Inc. (MBI) - Financial and Strategic SWOT Analysis                                                                                                Reference Code: GDME22296FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Med BioGene Inc., Recent Deals Summary ..................................................................................................................................... 32
       Section 5 – Company’s Recent Developments ...............
								
To top